{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:44:55Z","timestamp":1770831895587,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1110","license":[{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antipsychotics are a known cause of hyperprolactinaemia and can be associated with significant health issues in short term and long term. The effects vary with gender and age of the individual and can contribute towards non-concordance and hence relapse in mental health of our patients. Clinicians need to educate the patients about this significant side effect of not only antipsychotic medications but other medications causing hyperprolactinaemia commonly prescribed in primary care.<\/jats:p>","DOI":"10.1136\/postgradmedj-2017-135221","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T17:15:34Z","timestamp":1510247734000},"page":"226-229","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Antipsychotic-induced hyperprolactinaemia: case studies and review"],"prefix":"10.1093","volume":"94","author":[{"given":"Shweta","family":"Mittal","sequence":"first","affiliation":[{"name":"Consultant Psychiatrist, Department of Psychiatry, Bassetlaw Hospital, Nottinghamshire Healthcare NHS Foundation Trust , Worksop , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suveera","family":"Prasad","sequence":"additional","affiliation":[{"name":"Consultant Psychiatrist, Adult Mental Health Inpatient Unit, Rotherham Doncaster and South Humber Mental Health NHS Foundation Trust , Doncaster , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adwaita","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Consultant Psychiatrist, Adult Mental Health Inpatient Unit, Rotherham Doncaster and South Humber Mental Health NHS Foundation Trust , Doncaster , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacotherapy"},{"key":"2023041307354499000_","first-page":"232","article-title":"Atypical antipsychotics for mood and anxiety disorders: safe and effective adjuncts?","volume":"30","author":"Blier","year":"2005","journal-title":"J Psychiatry Neurosci"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4158\/EP.6.6.425","article-title":"Risperidone-associated hyperprolactinemia","volume":"6","author":"Kearns","year":"2000","journal-title":"Endocr Pract"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/schbul\/sbn023","article-title":"Secondary effects of antipsychotics: women at greater risk than men","volume":"35","author":"Seeman","year":"2009","journal-title":"Schizophr Bull"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5534\/wjmh.2012.30.3.153","article-title":"Antipsychotic-induced sexual dysfunction and its management","volume":"30","author":"Park","year":"2012","journal-title":"World J Mens Health"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2265.1998.00569.x","article-title":"Serum prolactin concentration in patients taking neuroleptic drugs","volume":"49","author":"Pollock","year":"1998","journal-title":"Clin Endocrinol"},{"key":"2023041307354499000_","first-page":"693","article-title":"Pattern of development of hyperprolactinemia after initiation of haloperidol therapy","volume":"91","author":"Spitzer","year":"1998","journal-title":"Obstet Gynecol"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0024-3205(02)01775-7","article-title":"Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia","volume":"71","author":"Meaney","year":"2002","journal-title":"Life Sci"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2826.2008.01736.x","article-title":"Prolactin: a pleiotropic neuroendocrine hormone","volume":"20","author":"Grattan","year":"2008","journal-title":"J Neuroendocrinol"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1530\/REP-10-0033","article-title":"Prolactin secretion patterns: basic mechanisms and clinical implications for reproduction","volume":"140","author":"Egli","year":"2010","journal-title":"Reproduction"},{"key":"2023041307354499000_","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"1 Pt 1","key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0013-7006(06)76142-5","article-title":"[Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone]","volume":"32","author":"Haefliger","year":"2006","journal-title":"Encephale"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2265.2010.03814.x","article-title":"Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management","volume":"74","author":"Holt","year":"2011","journal-title":"Clin Endocrinol"},{"issue":"2 Suppl","key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","article-title":"Antipsychotics and hyperprolactinaemia: clinical recommendations","volume":"22","author":"Peveler","year":"2008","journal-title":"J Psychopharmacol"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1600-0447.2006.00897.x","article-title":"Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders","volume":"115","author":"Eberhard","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1192\/bjp.182.3.199","article-title":"Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review","volume":"182","author":"Wieck","year":"2003","journal-title":"Br J Psychiatry"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","article-title":"Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects","volume":"9","author":"Halbreich","year":"2003","journal-title":"J Psychiatr Pract"},{"key":"2023041307354499000_","volume-title":"How to use anti-psychotic medication","author":"Nice Guidelines CG178 1.3.6"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1192\/apt.bp.113.012088","article-title":"Hyperprolactinaemia and antipsychotics","volume":"21","author":"Nelson","year":"2015","journal-title":"BJPscyh Advances"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am J Psychiatry"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1192\/pb.19.12.755","article-title":"Treatment of psychotropic-induced hyperprolactinaemia","volume":"19","author":"Duncan","year":"1995","journal-title":"Psychiatr Bull"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1192\/apt.bp.115.014928","article-title":"Management of antipsychotic-induced hyperprolactinaemia","volume":"23","author":"Gupta","year":"2017","journal-title":"BJPsych Advances"},{"key":"2023041307354499000_","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.encep.2012.03.002","article-title":"Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance","volume":"1","author":"Besnard","year":"2014","journal-title":"L\u2019Encephale"},{"key":"2023041307354499000_","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"Taylor","year":"2015"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/94\/1110\/226\/49838641\/postgradmedj-94-226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/94\/1110\/226\/49838641\/postgradmedj-94-226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:07:45Z","timestamp":1693210065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/94\/1110\/226\/6984598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":31,"journal-issue":{"issue":"1110","published-online":{"date-parts":[[2017,11,9]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2017-135221","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2017,11,9]]}}}